Effets indésirables cardiovasculaires des collyres à la phényléphrine en chirurgie ophtalmologique

Kauffmann, S.; Commun, F.; Schoeffler, P.; Chiambaretta, F.; Dewachter, Pascale

doi:10.1016/j.annfar.2012.12.009

Cited by 8 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the burden of the aforementioned cost of phenylephrine drops, eliminating exposure to unnecessary medication abrogates the potential for unwanted side effects. Although rare, allergic reactions to phenylephrine eye drops, systemic cardiovascular effects, and acute angle closure glaucoma have been reported and pose an unnecessary hazard upon at-risk patients, 19–22 particularly if there is no clear clinical benefit to adding phenylephrine for diagnostic dilation. These study results may offer a compelling reason to remove those risks, as sufficient conditions for examination can still be achieved without phenylephrine eye drops in certain patient populations.…”

Section: Discussionmentioning

confidence: 99%

Assessing the utility of 2.5% phenylephrine for diagnostic pupillary dilation

Liu

Green

Stavern

et al. 2017

Canadian Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Assessing the utility of 2.5% phenylephrine for diagnostic pupillary dilation

Liu

Green

Stavern

et al. 2017

Canadian Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…The use of phenylephrine increases the cost to conduct the examination and exposes patients to potential unwanted side effects, including systemic cardiovascular effects, allergic reactions, and acute angle closure glaucoma. 16–20 Ramsali et al 20 reported a patient who sustained a subarachnoid hemorrhage from systemic hypertension induced by phenylephrine use and noted that topical phenylephrine should be used cautiously, especially in elderly patients, with appropriate monitoring of hemodynamic status. 21 …”

Section: Discussionmentioning

confidence: 99%

Assessing the Clinical Requirement of 2.5% Phenylephrine for Diagnostic Pupil Examination

Cho

Brück

Liu

et al. 2021

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

Objective: To evaluate whether the standard dilating drop regimen consisting of phenylephrine, tropicamide, and proparacaine produces clinically significant improvement in pupil size compared to tropicamide and proparacaine during diagnostic eye examination. Methods: Sixty-three adult patients at Washington University School of Medicine Eye Clinic were enrolled in this prospective, randomized trial. Each patient received one of two dilating drop regimens: phenylephrine + tropicamide + proparacaine (PE+T+PP), which is considered the standard therapy, or tropicamide + proparacaine (T+PP). Main outcome measures were the proportion of pupils able to achieve successful clinical examination without need for additional dilating drops and change in predilation to postdilation pupil size. Comparisons were made using McNemar's test, repeated measures analysis of variance, and Fisher's test to determine whether PE is a necessary component of the standard eye examination. Results: There were no statistically significant differences between the PE+T+PP and T+PE treatment groups in predilation to postdilation changes in average resting pupil size (1.58-0.66 and 2.61-0.79; P = 0.57) or constricted pupil size (2.52-0.93 and 3.56-0.96; P = 0.15). There was no statistically significant difference between patients who obtained a successful dilated pupil examination between those receiving PE+T+PP and those receiving T+PP as determined by the examining physicians (Fisher's, P = 0.67). Conclusion: The addition of phenylephrine to tropicamide and proparacaine did not improve pupillary dilation size or ability to conduct a clinical examination. A single dilating agent using tropicamide should be considered in clinical practice.

show abstract

“…Ozgun and associates 2014 [ 19 ] reported a lethal case of diffuse necrotizing enterocolitis after topical application of drops containing 0.5% cyclopentolate and 1.25% phenylephrine. Phenylephrine, on the other hand, can cause hypertension, ECG changes and elevation in cardiac troponin Ic [ 20 ]. However, the case report in question seems to be exception, since a systematic review and meta-analysis [ 21 ] found no evidence that phenylephrine 2.5% evoked clinically relevant changes in heart rate, and the reported elevation in blood pressure was short lasting.…”

Section: Introductionmentioning

confidence: 99%

A Single Drop in the Eye – Effects on the Whole Body?

Vaajanen¹,

Vapaatalo²

2017

TOOPHTJ

View full text Add to dashboard Cite

Introduction:Although the local adverse effects of ophthalmic drugs, including allergic reactions, are well recognized, less is known about the systemic side- effects of eye drops, especially during pregnancy, breast-feeding and early childhood. Ophthalmologists should also be aware of unusual, in some cases even life-threatening, effects of commonly used eye drops.Conclusion:This brief review outlines the routes of systemic absorption and the kinetics of active components present in eye drops, and identifies the clinically relevant systemic adverse effects.

show abstract

Effets indésirables cardiovasculaires des collyres à la phényléphrine en chirurgie ophtalmologique

Cited by 8 publications

References 6 publications

Assessing the utility of 2.5% phenylephrine for diagnostic pupillary dilation

Assessing the utility of 2.5% phenylephrine for diagnostic pupillary dilation

Assessing the Clinical Requirement of 2.5% Phenylephrine for Diagnostic Pupil Examination

A Single Drop in the Eye – Effects on the Whole Body?

Contact Info

Product

Resources

About